Development of new diabetes drug halted by maker

Development of new diabetes drug halted by maker
Failure of aleglitazar might affect FDA deliberations on whether to ease restrictions on similar drug Avandia.

(HealthDay)—The development of what might have become a significant diabetes drug has been halted by its maker amid concerns that the medication raises the risk for fractures, kidney problems and heart failure in those taking it.

Roche reported Wednesday that it would shut down a late-stage clinical trial of the drug aleglitazar after a monitoring committee found signs of troubling side effects and a lack of effectiveness in patients with type 2 diabetes who had heart problems. The Swiss also closed all other studies of the drug.

"We are disappointed by this outcome as we hoped that aleglitazar would provide significant benefit for patients with who are at risk of cardiovascular disease," Dr. Hal Barron, chief medical officer at Roche, said in a company statement.

The drug was being tested to see if it could prevent heart attacks and strokes, in addition to lowering .

The failure of aleglitazar might color any decision the U.S. Food and Drug Administration may soon make about the troubled Avandia, which is similar to aleglitazar, The New York Times reported.

In 2010, Avandia's use was severely restricted in the United States because evidence suggested it raised the chances of heart attacks and stroke.

An FDA advisory committee recommended in June, however, that the restrictions on Avandia be eased. Thirteen members of the 26-person panel voted to ease the controls, while seven voted to lift them altogether. No decision on that recommendation has been made yet by the agency, although it often follows the advice of its expert panels.

Meanwhile, critics of Avandia argue that the entire class of drugs is dangerous and Avandia's use should remain tightly controlled, the Times reported.

Roche noted in its statement, however, that aleglitazar did not increase the risk of heart attacks or strokes, which may bolster the argument that Avandia also does not raise cardiovascular risks, the newspaper added.

In the aleglitazar study, more than 7,000 people with diabetes who had also suffered a recent heart attack or the onset or worsening of cardiac pain were involved. The study was supposed to last five years, until the beginning of 2015.

More information: For more on thiazolidinediones, the class of drugs to which Avandia belongs, visit the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.

add to favorites email to friend print save as pdf

Related Stories

US experts review heart attack risk of diabetes drug

Jun 05, 2013

GlaxoSmithKline's controversial diabetes drug Avandia, restricted in the US and banned in Europe over concerns it raises heart attack risk, is getting a second look this week by US medical experts.

US panel wants changes to Avandia safety measures (Update)

Jun 06, 2013

US government health experts are recommending changes to safety restrictions on former blockbuster diabetes pill Avandia, in light of a new analysis suggesting that the drug may not increase the risk of heart attack as previously ...

US panel backs novel diabetes pill from J&J (Update)

Jan 10, 2013

A panel of U.S. health experts ruled Thursday that an experimental diabetes drug from Johnson & Johnson is safe and effective, though lingering safety questions must be tracked over the long term.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

8 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments